CapZ

• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ASH 65th Annual meeting.Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively.Preclinical data on HSPC gene therapy and a comprehensive analysis of TALE-BE editing determinants presented at ESGCT 2023 30th annual congress.Preclinical data on Multi-armored Allogeneic MUC1-CAR T-cells targeting Triple-Negative Breast at SITC 2023 annual event.Cash position of $721 million as of September 30, 2023. Cash runway into 2026 including Initial AstraZeneca Investment and Potential Additional AstraZeneca Investment.Conference call scheduled for 8.00am ET / 2.00 pm CET on November 7, 2023 NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and financial results for the nine-month period ending September 30, 2023. On November 1st 2023, Cellectis and AstraZeneca Holdings B.V. (“AstraZeneca”) entered into a joint research collaboration agreement (the “Collaboration Agreement”), pursuant to which AstraZeneca makes an upfront payment of $25 million, an investment agreement relating to an initial equity investment of $80 million (the “Initial Investment Agreement”) and a non-binding memorandum of understanding relating to an additional equity investment subject to conditions set forth in the MOU of $140 millions (the “MOU”). This research collaboration will leverage Cellectis’ gene editing technologies and manufacturing capabilities to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Cellectis has exclusively reserved 25 genetic targets for AstraZeneca, from which up to 10 novel candidate products could be explored for development. Cellectis’ clinical-stage assets, UCART22, UCART123 and UCART20x22 will remain under Cellectis’ ownership and control. Pipeline Highlights UCART Clinical Development Programs BALLI-01 (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Cellectis will present a poster at the ASH Annual Meeting with updated results of the Phase I BALLI-01 Trial of UCART22 (P2), an anti-CD22 allogeneic CAR T- cell product manufactured in-house, in patients with relapsed or refractory (r/r) CD22+ B-Cell acute lymphoblastic leukemia (B-ALL). The poster presentation highlights the following data: In vitro comparability studies suggested that UCART22 process 2 (P2) (manufactured in-house) is more potent than UCART22 process 1 (P1) (manufactured by an external CDMO), and as of July 1st, 2023, 3 patients were enrolled into the first UCART22 P2 cohort at dose level 2 (1 million cells/kg).UCART22 P2 was administered after fludarabine, cyclophosphamide, and alemtuzumab (FCA) lymphodepletion and was well tolerated. No DLTs or ICANS was observed, and the CRS observed was Grade 1 or 2.There was a higher preliminary response rate (67%) at dose level 2 with one million cells/kg with UCART22 P2 compared to 50% response rate with a dose 5 times higher at dose level 3 of UCART22 P1 that was manufactured by an external CDMO.UCART22 expansion was observed in the responding patients and correlated with increases in serum cytokines and inflammatory markers.The study continues to enroll patients at dose level 2i (2.5 million cells/kg) with UCART22 P2. NATHALI-01 (evaluating UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) Cellectis will present a poster at the ASH Annual Meeting with the initial preliminary results from the NATHALI-01 trial (NCT05607420), a Phase 1/2a dose-finding and expansion study evaluating UCART20x22 in r/r B-cell NHL. The poster presentation highlights the following data: As of July 1st, 2023, 3 patients were enrolled and treated at dose level 1 (50 million cells). Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment. No immune effector cell associated neurotoxicity (ICANS) or graft versus host disease (GvHD) was observed. There were no UCART20x22 dose limiting toxicities (DLTs), and there was 1 DLT in connection with CLLS52 (alemtuzumab).All patients responded at Day 28, with 1 partial metabolic response and 2 complete metabolic responses in patients who had failed prior autologous CD19 CAR T-cell therapies.UCART20x22 expansion correlated with increases in serum cytokine and inflammatory marker levels as well as with CRS.These initial data support the continued study of UCART20x22 in r/r B-cell NHL. AMELI-01 (evaluating UCART123) in relapsed or refractory acute myeloid leukemia (r/r AML) UCART123 is an allogeneic CAR T-cell product candidate targeting CD123 and is being evaluated in patients with r/r AML in the AMELI-01 Phase 1 dose-escalation clinical study.The AMELI-01 study is currently enrolling patients after FCA lymphodepletion in a two-dose regimen arm. Research Data & Preclinical Programs Cellectis announced the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in Activated phosphoinositide 3-kinase delta syndrome 1 (APDS1) T-cells.Cellectis presented encouraging data on gene editing process using TALEN®-based gene editing platform, to overcome the challenges of the “cold” tumor microenvironment in a poster at the CICON 2023 (CRI-ENCI-AACR 7th International Cancer Immunotherapy Conference).Cellectis presented preclinical data on MUC1-CAR T-cells to overcome key challenges of targeting solid tumors in a poster session at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).Cellectis presented preclinical data on its program of gene therapy for HSPC at the European Society of Gene and Cell Therapy (ESGCT) 30th annual congress.Cellectis presented a comprehensive analysis of TALE-BE editing determinants at the European Society of gene and Cell Therapy (ESGST) 30th annual congress. Licensed Allogeneic CAR T-cell Development Programs Allogene Therapeutics, Inc.’s CAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products that were jointly developed under a collaboration agreement between Les Laboratoires Servier (“Servier”) and Allogene Therapeutics, Inc. (“Allogene”) until 15 December 2022 based on an exclusive license granted by Cellectis to Servier2. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S., Allogene continues the development for this territory while Servier retains exclusive rights for all other countries. Allogene’s anti-CD70 and anti-Claudin18.2 programs are licensed exclusively from Cellectis to Allogene and Allogene holds global development and commercial rights to these programs. Servier and Allogene: anti-CD19 programs Allogene announced that its ALPHA2 study will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy.Allogene announced it will have two poster presentations from the ALPHA/ALPHA2 trials focused on lymphodepletion in allogeneic cell therapy at ASH 2023. The first poster is a comprehensive safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory (r/r) Large B Cell Lymphoma (LBCL) and follicular lymphoma (FL) to characterize the overall safety profile when ALLO-647 is added to standard lymphodepletion. The second poster showcases translational results from ALPHA2 generated through a collaboration with MD Anderson Cancer Center. This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with the ALLO-501A product candidate in the ALPHA2 trial. According to Allogene, this study revealed the impact of recipient alloreactive CD8+ T cells in allogeneic CAR T rejection and the results of this study could help define strategies to improve allogeneic CAR T expansion, persistence and efficacy. Allogene: anti-CD70 and anti-Claudin18.2 programs Allogene announced that the Phase 1 dose escalation TRAVERSE trial in patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed on standard therapies including an immune checkpoint inhibitor and a VEGF-targeting therapy is ongoing.Allogene announced that SITC 2023 will include a review of research which provided early validation of ALLO-182, an AlloCAR T candidate currently in the IND-enabling phase of development targeting Claudin18.2 for the treatment of patients with gastric and pancreatic cancers. Corporate Updates Strategic Collaboration and Investment Agreements with AstraZeneca Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products. As part of the Collaboration Agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development. AstraZeneca will have an option for a worldwide exclusive license on the candidate products, to be exercised before IND filing. Cellectis’ clinical-stage assets, UCART22, UCART123 and UCART20x22 will remain under Cellectis’ ownership and control. Pursuant to the Collaboration Agreement, Cellectis’ research costs under the collaboration will be funded by AstraZeneca and Cellectis will receive an upfront payment of $25 million. Under the terms of the Collaboration Agreement, Cellectis is also eligible to receive an investigational new drug (IND) option fee and development, regulatory and sales-related milestone payments, ranging from $70 million up to $220 million, per each of the 10 candidate products, plus tiered royalties. As a condition to the signing of the Collaboration Agreement, AstraZeneca has agreed to make an initial equity investment of $80 million in Cellectis by subscribing for 16,000,000 ordinary shares, at a price of $5.00 per share (the “Initial Investment”). The new shares are issued to AstraZeneca by the board of directors of Cellectis pursuant to the 17th resolution of Cellectis’ shareholders meeting held on June 27, 2023. Following settlement and delivery of the new shares (expected to be on November 6, 2023), AstraZeneca will own approximately 22% of the share capital, and 21% of the voting rights of the Company, will have the right to nominate a non-voting observer on the board of directors of Cellectis, and will have the right to participate pro rata in Cellectis’s future share offerings. Additionally, the MOU contemplates that AstraZeneca will make a potential further equity investment in Cellectis of $140 million by subscribing for two newly created classes of convertible preferred shares of Cellectis: 10,000,000 “class A” convertible preferred shares and 18,000,000 “class B” convertible preferred shares, in each case at a price of $5.00 per share (the “Additional Investment”). Until they convert into ordinary shares, the “class A" convertible preferred shares would have single voting rights and would not carry any double voting right at any moment, and the “class B” would carry no voting rights except on any distribution of dividends or reserves. Both class of preferred shares would enjoy a liquidation preference (if any liquidation surplus remains after repayment of Cellectis’ creditors and of par value to all shareholders) and would be convertible into the same number of ordinary shares with the same rights as the outstanding ordinary shares. The MOU is non-binding and the Additional Investment remains to be confirmed by both parties following a consultation process with Cellectis’ works council. If confirmed, the closing of the Additional Investment will remain subject to (i) Cellectis’ shareholders’ approval at a two-thirds majority of the votes cast by voting shareholders, (ii) clearance of such investment from the French Ministry of Economy according to the foreign direct investment French regulations, and (iii) other customary closing conditions. Immediately following the Additional Investment, it is anticipated that AstraZeneca would own approximately 44% of the share capital of the Company and 30% of the voting rights of the Company (based on the number of voting rights outstanding immediately after the completion of the Initial Investment) and would have the right to nominate two directors to the board of directors of Cellectis. Further, certain business decisions are subject to AstraZeneca’s approval, including, in particular, winding up any company of the Cellectis group, issuing securities senior to or pari passu with the convertible preferred shares or any shares without offering AstraZeneca the option to purchase its pro rata share of such securities (subject to customary exceptions, including issuances under employee equity incentive plans), declaring or paying dividends, prepaying indebtedness before due, and disposing of any material assets concerning gene editing tools or manufacturing facilities and selling, assigning, licensing, encumbering or otherwise disposing of certain material IP rights. Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”). On January 13, 2023, Calyxt, Cibus Global LLC (Cibus) and certain other parties named therein, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction (the “Calyxt Merger”). As a consequence of the foregoing, Calyxt met the “held-for-sale” criteria specified in IFRS 5 and was classified as a discontinued operation until May 31, 2023. On June 1, 2023, Calyxt and Cibus closed the merger transaction and now operate under the name Cibus, Inc. Consequently, Calyxt was deconsolidated and Calyxt's cash, cash equivalent and restricted cash are no longer included in the Group's cash, cash equivalent and restricted cash since June 1, 2023. As from June 1, 2023 and the deconsolidation of Calyxt, which corresponded to the Plants operating segment, we view our operations and manage our business in a single operating and reportable segment corresponding to the Therapeutics segment. For this reason, we are no longer presenting financial measures broken down between our two reportable segments - Therapeutics and Plants. The results of Calyxt until the date of deconsolidation are isolated under “Income (loss) from discontinued operations” in the appendices of this Q3 2023 financial results press release. Cash: As of September 30, 2023, Cellectis, had $72 million in consolidated cash, cash equivalents, and restricted cash. This compares to $95 million in consolidated cash, cash equivalents and restricted cash as of December 31, 2022. This $23 million difference mainly reflects $79 million of cash out, which include $23 million for R&D suppliers, $12 million for SG&A suppliers, $32 million for staff costs, $8 million for rents and taxes, $4 millions of reimbursement of the “PGE” loan, and a $2 million unfavorable impact on Forex partially offset by a $23 million net cash inflow from the capital raise closed in February, a $21 million net cash inflow from EIB loan, a $6 million of net cash received from research tax credit prefinancing, a $1 million cash inflow related to the grant and refundable advance from BPI, $3 millions of financial investments’ capital gain and interests, a $1 million reimbursement of social charges paid on stock options, and a $2 million net cash inflow from licenses and other cash receipts. With cash and cash equivalents of $67.4 million as of September 30, 2023, our anticipated borrowing of €15.0 million under Tranche B of the €40.0 million Finance Contract with EIB and the $105 million from AstraZeneca's agreements, the Company believes it has sufficient resources to continue operating for at least twelve months following the consolidated financial statements’ publication. Additionally, the MOU contemplates that AstraZeneca will make a potential further equity investment in Cellectis of $140M by subscribing for two newly created classes of convertible preferred shares of Cellectis (the “Additional Investment”). The MOU is non-binding and the Additional Investment remains to be confirmed by both parties following a consultation process with Cellectis’ works council. If confirmed, the closing of the Additional Investment will remain subject to (i) Cellectis’ shareholders’ approval at a two-thirds majority of the votes cast by voting shareholders, (ii) clearance of such investment from the French Ministry of Economy according to the foreign direct investment French regulations, and (iii) other customary closing conditions. With cash and cash equivalents of $67.4 million as of September 30, 2023, our anticipated borrowing of €15.0 million under Tranche B of the €40.0 million Finance Contract with EIB and the $105 million from AstraZeneca's payments under the Collaboration Agreement and the Initial Investment Agreement, the Company believes it has sufficient resources to continue operating until Q2 2025. Concurrent with the potential additional $140 million, we expect that the Company would extend its cash runway into 2026. Revenues and Other Income: Consolidated revenues and other income were $7.2 million for the nine months ended September 30, 2023 compared to $8.4 million for the nine months ended September 30, 2022. The decrease of $1.0 million reflects the recognition of two milestones related to Cellectis’ agreement with Cytovia for $1.5 million in 2022 and a milestone of $1.0 million with another partner while recognition of revenues in 2023 is not material, and partially offset by the increase of the research tax credit for $0.6 million and the partial recognition of a grant signed with “BPI” of $0.8 million. R&D Expenses: Consolidated R&D expenses were $62.1 million for the nine months ended September 30, 2023, compared to $76.1 million for the nine months ended September 30, 2022. The $13.9 million decrease was primarily attributable to (i) a $8.9 million decrease in personal expenses due to departures not replaced and decrease in stock-based compensation expenses consecutive to the non-achievement of certain performance obligations of October 2020 free shares plan (ii) a $5.0 million decrease in purchases, external expenses and other (from $41.4 million in 2022 to $36.4 million in 2023) mainly due to continuing internalization of our manufacturing and quality activities to support our R&D pipeline. SG&A Expenses: Consolidated SG&A expenses were $12.1 million for the nine months ended September 30, 2023, compared to $15.8 million for the nine months ended September 30, 2022. The $3.7 million decrease primarily reflects (i) a $2.4 million decrease in purchases, external expenses and (from $9.5 million in 2022 to $7.1 million in 2023) mainly explained by the implementation of our ERP in 2022 (ii) a $1.3 million decrease in personal expenses and non-cash stock-based compensation expenses. Net financial gain (loss): Consolidated net financial gain was $14.9 million for the nine months ended September 30, 2023, compared to 11.0 million for the nine months ended September 30, 2022. The $3.9 million increase primarily reflects (i) a $22.8 million increase of financial income, mainly attributable to the profit from Calyxt’s deconsolidation, partially offset by (ii) the loss in fair value on our retained investment in Calyxt since deconsolidation for $6.2 million, (iii) a $7.9 million decrease in the net value of Cytovia’s note receivable. Net income (loss) from discontinued operations: Pursuant to Calyxt deconsolidation income from discontinued operation for the nine-month period ended September 30, 2023, 2023 only include five months of activity. The $2.2 million decrease in net loss from discontinued operations between the nine-month periods ended September 30, 2022 and 2023 is primarily driven by Calyxt's $5.7M net loss in the third quarter of 2022 compared with $0 in the third quarter of 2023 as Calyxt was deconsolidated, partially offset by a 3.5M$ increase in the net loss over the first two quarters between 2022 and 2023. This $3.5M increase breaks down as follows: (i) an increase of $9.2 million of net financial loss and (ii) an increase of $1.5 million of other operating expenses, partially offset by (i) a decrease of $2.8 million of R&D expenses (from $6.3 million in 2022 to $3.5 million in 2023) and (ii) a decrease of $4.5 million of SG&A expenses (from $6.8 million in 2022 to $2.3 million in 2023). Net Income (loss) Attributable to Shareholders of Cellectis: The consolidated net loss attributable to shareholders of Cellectis was $58.2 million (or $1.07 per share) for the nine months ended September 30, 2023, of which $53.2 million was attributed to Cellectis continuing operations, compared to $79.3 million (or $1.74 per share) for the nine months ended September 30, 2022, of which $72.9 million was attributed to Cellectis continuing operations. This $21.1 million decrease in net loss between the first nine months of 2023 and 2022 was primarily driven by (i) a $13.9 million decrease of R&D expenses, (ii) a $3.7 million decrease of SG&A expense, (iii) an increase of $3.9 million of the financial gain due to the deconsolidation of Calyxt compensated in part by the decrease of fair value of Cytovia’s note receivable and, (iv) a decrease of $2.2 million of loss from discontinued operations attributable to Shareholders of Cellectis. These downward impacts on the net loss were partially offset by (i) a decrease of $1.2 million of revenues and other income. Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: The consolidated adjusted net loss attributable to shareholders of Cellectis was $56.8 million (or $1.05 per share) for the nine months ended September 30, 2023, compared to a net loss of $72.1 million (or $1.58 per share) for the nine months ended September 30, 2022. Please see "Note Regarding Use of Non-IFRS Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis. We currently foresee focusing our cash spending at Cellectis for 2023 in the following areas: Supporting the development of our pipeline of product candidates, including the manufacturing and clinical trial expenses of UCART123, UCART22, UCART 20x22 and potential new product candidates;Operating our state-of-the-art manufacturing capabilities in Paris (France), and Raleigh (North Carolina, USA); andContinuing to strengthen our manufacturing and clinical departments. CELLECTIS S.A. STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited) ($ in thousands) As of December 31, 2022 September 30, 2023 ASSETS Non-current assets Intangible assets 718 662 Property, plant, and equipment 63,621 56,774 Right-of-use assets 44,275 39,146 Non-current financial assets 8,791 16,624 Total non-current assets 117,406 113,205 Current assets Trade receivables 772 393 Subsidies receivables 14,496 20,255 Other current assets 9,078 8,488 Cash and cash equivalent and Current financial assets 97,697 67,358 Total current assets 122,043 96,494 Total assets held for sale 21,768 0 TOTAL ASSETS 261,216 209,700 LIABILITIES Shareholders’ equity Share capital 2,955 3,492 Premiums related to the share capital 583,122 473,325 Currency translation adjustment (28,605) (37,505)Retained earnings (333,365) (304,994)Net income (loss) (106,139) (58,197)Total shareholders’ equity - Group Share 117,968 76,123 Non-controlling interests 7,973 0 Total shareholders’ equity 125,941 76,123 Non-current liabilities Non-current financial liabilities 20,531 43,248 Non-current lease debts 49,358 43,816 Non-current provisions 2,390 2,560 Total non-current liabilities 72,279 89,625 Current liabilities Current financial liabilities 5,088 5,058 Current lease debts 7,872 8,203 Trade payables 21,456 20,476 Deferred revenues and deferred income 59 117 Current provisions 477 946 Other current liabilities 13,179 9,153 Total current liabilities 48,131 43,953 Total liabilities related to asset held for sale 14,864 0 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 261,216 209,700 Cellectis S.A.UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the three-month period ended September 30, 2023$ in thousands, except per share amounts For the three-month period endedSeptember 30, 2022 * 2023 Revenues and other income Revenues 175 155 Other income 1,704 1,489 Total revenues and other income 1,879 1,644 Operating expenses Cost of revenue (367) (181)Research and development expenses (23,837) (18,894)Selling, general and administrative expenses (4,903) (3,227)Other operating income (expenses) (125) (12)Total operating expenses (29,233) (22,314) Operating income (loss) (27,353) (20,671) Financial gain (loss) 1,807 3,295 Income tax 0 (106)Income (loss) from continuing operations (25,548) (17,482)Income (loss) from discontinued operations (5,718) 0 Net income (loss) (31,265) (17,482)Attributable to shareholders of Cellectis (28,467) (17,482)Attributable to non-controlling interests (2,798) (0)Basic net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.63) (0.31) Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.63) (0.31) Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) (0.06) 0.00 Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) (0.06) 0.00 * These amounts reflect adjustments made in connection with the presentation of the discontinued operation Cellectis S.A.UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the nine-month period ended September, 2023$ in thousands, except per share amounts For the nine-month period endedSeptember 30, 2022 * 2023 Revenues and other income Revenues 3,147 472 Other income 5,255 6,731 Total revenues and other income 8,402 7,.203 Operating expenses Cost of revenue (1,081) (570)Research and development expenses (76,067) (62,119)Selling, general and administrative expenses (15,797) (12,141)Other operating income (expenses) 649 (96)Total operating expenses (92,297) (74,926) Operating income (loss) (83,894) (67,723) Financial gain (loss) 11,019 14,875 Income tax 0 (365)Income (loss) from continuing operations (72,875) (53,213)Income (loss) from discontinued operations (12,601) (10,377)Net income (loss) (85,476) (63,590)Attributable to shareholders of Cellectis (79,326) (58,197)Attributable to non-controlling interests (6,150) (5,393)Basic net income (loss) attributable to shareholders of Cellectis, per share ($/share) (1.74) (1.07) Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share) (1.74) (1.07) Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) (0.14) (0.09) Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) (0.14) (0.09) * These amounts reflect adjustments made in connection with the presentation of the discontinued operation Note Regarding Use of Non-IFRS Financial Measures Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis RECONCILIATION OF IFRS TO NON-IFRS NET INCOMEFor the three-month period ended September 30, 2023(unaudited) - ($ in thousands except per share data) For the three-month period endedSeptember 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (28,467) (17,482)Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 1,880 (2,653)Adjusted net income (loss) attributable to shareholders of Cellectis (26,587) (20,135) Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.58) (0.37)Basic adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($ /share) (0.05) 0.00 Weighted average number of outstanding shares, basic (units) 45,540,315 55.583.768 Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.58) (0.36)Diluted adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($/share) (0.05) 0.00 Weighted average number of outstanding shares, diluted (units) 45,540,315 55.583.768 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited) For the nine-month period ended September 30, 2023 ($ in thousands, except per share data) For the nine-month period endedSeptember 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (79,326) (58,197)Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 7,211 1,400 Adjusted net income (loss) attributable to shareholders of Cellectis (72,115) (56,797) Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.58) (1.05)Basic adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($ /share) (0.11) (0.08) Weighted average number of outstanding shares, basic (units) 45,511,626 54,231,943 Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.58) (1.05)Diluted adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($/share) (0.11) (0.08) Weighted average number of outstanding shares, diluted (units) 45,511,626 54,231,943 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). Forward-looking StatementsThis press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate”, “expect”, “plan”, “could”, “will,” “accelerate,” “suggest,” “eligible,” “encouraging”, “believe”, subject to,” “potential,” “up to,” and “may” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners. Forward-looking statements include statements about the potential payments for which Cellectis is eligible under the Collaboration Agreement; the possible size of the proposed equity investment by AstraZeneca, the preliminary results for the NATHALI-01 and BALLI-01 clinical trials and the objectives of such trials, which remain ongoing; the ability to progress our clinical trials and to present any additional data from these trials; clinical outcomes from our clinical trials, which may materially change as more patient data becomes available, potential benefits of our UCART product candidates, the operational capabilities at our manufacturing facilities, and the sufficiency of cash to fund our operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including (i) the numerous risks associated with biopharmaceutical product candidate development, (ii) with respect to the AstraZeneca agreements, the risk that conditions to closing, including necessary regulatory approvals, are not satisfied in a timely manner or at all; the risks arising from Cellectis’s reliance on AstraZeneca to conduct certain development and commercialization activities, including the potential for disagreements or disputes under the Collaboration Agreement; the risk that AstraZeneca may exercise its discretion in a manner that limits the resources contributed toward the development of certain projects under the Collaboration Agreement or may exercise its faculty to terminate without cause the Agreement; the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data; and the risk that the Company may not be able to secure additional capital on attractive terms, if at all, and (iii) our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2022 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact:     Media contact:       Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com  Investor Relations contacts:       Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com       Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  1 Cash position includes cash, cash equivalents and restricted cash. Restricted cash was $5 million as of September 30, 2023.2 Servier is a global independent pharmaceutical group. Attachment Press release earnings Q3 2023_ENGLISH

Preclinical Posters to Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on the Next Generation AlloCAR T™ Platform Cloak ™ and Dagger™ Technologies Highlighted Potential to Enhance Engraftment, Expansion and Persistence of AlloCAR T Cells Preclinical Validation of ALLO-182, an AlloCAR T Candidate Targeting Claudin18.2 for the Treatment of Gastric and Pancreatic Cancers Posters Announced for the Upcoming Annual Meeting of the American Society of Hematology, Including Comprehensive Review of Overall Safety Pro our ALLO-501/501A Candidates Used in Conjunction with Propriety Lymphodepletion With Investigational ALLO-647 From the Phase 1 ALPHA/ALPHA2 Studies Enrollment Continues in the Global ALPHA2 Phase 2 Trial with ALLO-501A in LBCL with Clinical Sites Open in the United States, Canada, Europe and Australia Ended Q3 2023 with $497.7 Million in Cash, Cash Equivalents and Investments with Continued Cash Runway Projection into the Second Half of 2025 Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2023. “Our experience continues to deepen as we successfully execute across our platform, creating a code for allogeneic cell therapy that can be applied not just in the industry’s first potentially pivotal trial of an allogeneic CAR T product candidate, but in other harder modes such as earlier line trials, solid tumors, and next-generation products and indications,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “We look forward to the months ahead and sharing these insights, potentially unlocking new opportunities and broadening patient access to CAR T therapy.” Pipeline Updates Anti-CD19 AlloCAR T Program ALPHA2 is the industry’s first potentially pivotal Phase 2 allogeneic CAR T clinical trial. This global trial for the ALLO-501A product candidate will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy. The single-arm ALPHA2 trial in relapsed/refractory (R/R) large B cell lymphoma (LBCL) utilizes a single dose of ALLO-501A (120 million CAR+ cells) following lymphodepletion with FCA90 (fludarabine, 30 mg/m2; cyclophosphamide 300 mg/m2; and investigational ALLO-647 30 mg, daily for 3 days). The primary endpoint is overall response rate (ORR), and the key secondary endpoint is duration of response (DoR). Patients may receive treatment as an outpatient at the investigator’s discretion. Enrollment is expected to be completed by the 1H 2024 with the first data readout by the end of 2024. The Company announced it will have two poster presentations from the ALPHA/ALPHA2 trials focused on lymphodepletion in allogeneic cell therapy at the 65th Annual Meeting of the American Society of Hematology (ASH) December 2023. The first poster is a comprehensive safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory (r/r) Large B Cell Lymphoma (LBCL) and follicular lymphoma (FL) to characterize the overall safety pro ALLO-647 is added to standard lymphodepletion. The second poster showcases translational results from ALPHA2 generated through a collaboration with The University of Texas MD Anderson Cancer Center. This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with the ALLO-501A product candidate in the ALPHA2 trial. The study revealed the impact of recipient alloreactive CD8+ T cells in allogeneic CAR T rejection. Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence and efficacy. Long-term follow up data was previously presented from the Phase 1 ALPHA/ALPHA2 trials in LBCL and has been extensively characterized in presentations earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting, European Hematology Association Congress, and International Conference on Malignant Lymphoma (ICML) in Lugano. The Phase 1 trials enrolled heavily pre-treated patients with a median of three prior lines of therapy. Data from 33 CAR T-naïve LBCL patients receiving Alloy™ cell product, including 12 patients treated with the Phase 2 regimen, are the first to demonstrate the potential for an investigational allogeneic CAR T product to induce complete responses at rates and durability similar to approved autologous therapies. Treatment with the ALLO-501/501A product candidates was generally well tolerated with no incidence of Grade 3 or greater cytokine release syndrome, and no cases of immune effector cell-associated neurotoxicity syndrome or graft versus host disease. Cytopenia and infections were manageable and comparable to the experience with autologous CAR T cell therapies in patients with r/r LBCL. The EXPAND trial, enrolling in the United States and Europe, is expected to support licensure of ALLO-647, the Company’s investigational anti-CD52 monoclonal antibody used in conjunction with standard low-dose FC (fludarabine, 30 mg/m2 and cyclophosphamide 300 mg/m2, daily for 3 days) lymphodepletion regimens. The trial will enroll approximately 70 patients with r/r LBCL who will be randomized to lymphodepletion with FCA90 (which includes 90 mg of ALLO-647) versus FC alone before receiving a single 120 million cell dose of ALLO-501A. The primary endpoint of the study is progression free survival (PFS). Anti-CD70 AlloCAR T Program The Phase 1 dose escalation TRAVERSE trial in patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed on standard therapies including an immune checkpoint inhibitor and a VEGF-targeting therapy is ongoing. Dose escalation in the TRAVERSE trial is expected to be completed by early 2024. The Company intends to target an academic forum in early 2024 to provide an update from this trial. Next Generation Technologies and Targets Cloak™ and Dagger™ Platform Technologies The Company recently announced three poster presentations from its next generation AlloCAR T Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will spotlight its novel, targeted Cloak and Dagger platform technologies designed to enhance engraftment, expansion and persistence of AlloCAR T cells. These innovative approaches are intended to simplify lymphodepletion for allogeneic CAR T products and may provide a path to further expand the potential of off-the-shelf CAR T products beyond current targets and indications. The Cloak platform technology is designed to prevent AlloCAR T cells from being recognized by host T cells without triggering substantial natural killer (NK) cell rejection while preserving CAR T cell function. The Dagger™ platform technology, a feature of our ALLO-316 candidate, is designed to engineer AlloCAR T cells to selectively eliminate CD70 positive, alloreactive host immune cells, thereby mitigating potential premature rejection of AlloCAR T cells by the patient’s immune system. Translational results shared at AACR suggest this unique immunomodulatory effect of ALLO-316 contributed to robust AlloCAR T cell expansion and persistence, and clinical remissions. Based on preclinical results demonstrating the ability to combine anti-CD19 and other AlloCARs™ with the Dagger technology, the Company intends to explore this approach to potentially enhance the activity of next generation AlloCAR T products candidates, including those that target other hematological and solid tumors. ALLO-182 SITC will also include a review of research which provided early validation of ALLO-182, an AlloCAR T candidate currently in the IND-enabling phase of development targeting Claudin18.2 for the treatment of patients with gastric and pancreatic cancers. Corporate Updates The Company has recently announced two new appointments to the leadership team. In August, the Company announced Earl Douglas as General Counsel, overseeing all aspects of the Company’s legal function. Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities. Third Quarter Financial Results The Company had $497.7 million in cash, cash equivalents, and investments as of September 30, 2023. Research and development expenses were $46.0 million for the third quarter of 2023, which includes $6.7 million of non-cash stock-based compensation expense. General and administrative expenses were $17.0 million for the third quarter of 2023, which includes $8.6 million of non-cash stock-based compensation expense. Net loss for the third quarter of 2023 was $61.3 million, or $0.37 per share, including non-cash stock-based compensation expense of $15.4 million. 2023 Financial Guidance As previously provided, the Company expects a decrease in cash, cash equivalents, and investments of approximately $230 million in 2023. Based on current assumptions, the Company continues to expect its cash runway to fund operations into 2H 2025. GAAP Operating Expenses are expected to be approximately $340 million, including estimated non-cash stock-based compensation expense of approximately $80 million. These estimates exclude any impact from potential business development activities. Conference Call and Webcast Details Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update. If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call, which will identify you as the participant and allow you the option to ask a question. The listen-only webcast will be made available on the Company's website at under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X (formerly Twitter) and LinkedIn. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," “projects,” "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: ALPHA2 being a potentially pivotal trial; the pace, timing and extent to which we may enroll patients in our clinical trials or release data from such trials; the timing and ability to progress the ALPHA2 and TRAVERSE trials; clinical outcomes, which may materially change as more patient data become available; the design and potential benefits of our Cloak ™ and Dagger™ technologies including the ability to enhance engraftment, expansion and persistence of AlloCAR T cells or the ability to resist rejection of AlloCAR T cells by the host immune cells and the expected benefits therefrom, and our plans to deploy Cloak ™ and Dagger™ technologies; the potential for our product candidates to be approved; the potential benefits of AlloCAR T products; the ability of our product candidates to treat various stages and types of cancers including hematological and solid tumors or gastric and pancreatic cancers; our level of operating expenses and the extent of our cash runway; our ability to expand indications for our allogeneic CAR T product candidates; our ability to broaden patient access to CAR T therapy; the modes of action or the biologic impacts of our product candidates including the engraftment, expansion, persistence and efficacy of allogeneic CAR T cells, the ability of AlloCAR T cells from being recognized by host T cells without triggering an immune response, and the ability to selectively eliminate CD70 positive alloreactive host immune cells; the incidence, severity and manageability of side effects of allogeneic CAR T therapies; the extent to which our clinical trials will support regulatory approval of our product candidates; the extent to which and type of lymphodepletion strategies that may be required in conjunction with our product candidates; the potential for off-the-shelf CAR T products; our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; Servier’s discontinuation of its involvement in the development of all CD19 products pursuant to our Exclusive License and Collaboration Agreement and our disputes with Servier may have adverse consequences; the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trial; our ability to maintain intellectual property rights necessary for the continued development of our product candidates, including pursuant to our license agreements; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; challenges with manufacturing or optimizing manufacturing of our product candidates; and our ability to obtain additional financing to develop our products and implement our operating plans. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Annual Report on Form 10-K for the year ended December 31, 2022, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, being filed with the SEC today. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Caution should be exercised regarding statements comparing autologous CAR T data. There are differences in the clinical trial design, patient populations, published data, follow-up times and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results. AlloCAR T™, AlloCAR™, Cloak™ and Dagger™ are trademarks of Allogene Therapeutics, Inc. Allogene’s AlloCAR T™ programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. The anti-CD70 and anti-Claudin18.2 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs. ALLOGENE THERAPEUTICS, INC. SELECTED FINANCIAL DATA (unaudited; in thousands, except share and per share data) STATEMENTS OF OPERATIONS Three Months Ended September 30, 2023 2022 Collaboration revenue - related party $ 43 $ 49 Operating expenses: Research and development $ 45,977 $ 63,641 General and administrative 17,041 18,897 Total operating expenses 63,018 82,538 Loss from operations (62,975 ) (82,489 ) Other income (expense), net: Interest and other income, net 6,205 1,002 Other expenses (4,545 ) (1,661 ) Total other income (expense), net 1,660 (659 ) Net loss (61,315 ) (83,148 ) Net loss per share, basic and diluted $ (0.37 ) $ (0.58 ) Weighted-average number of shares used in computing net loss per share, basic and diluted 167,649,010 143,661,721 SELECTED BALANCE SHEET DATA As of September 30, 2023 As of December 31, 2022 Cash, cash equivalents and investments $ 497,675 $ 576,471 Total assets 712,326 817,079 Total liabilities 129,224 151,209 Total stockholders’ equity 583,102 665,870 Allogene Media/Investor Contact: Christine Cassiano EVP, Chief Corporate Affairs & Brand Strategy Officer Christine.Cassiano@allogene.com

Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event Appointment of Cécile Chartier, Ph.D., as Director to Cellectis’ Board of Directors Cash position1 of $89 million as of June 30, 2023. Cash runway into Q3 2024 Full financial statements for the second quarter of 2023 will be released in the coming days Conference call scheduled for 8AM ET/2PM CET on August 4, 2023 NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business updates and preliminary financial results for the six-month period ending June 30, 2023. Full report of the financial results for the second quarter of 2023 will be released in the coming days. “We are proud of our team and the strong execution this quarter. Our clinical data presented for UCART22 at the European Hematology Association (EHA) were positive for patients with r/r B-ALL who have failed multiple lines of treatment including multi-agent chemoimmunotherapy, CD19 directed CAR T-cell therapy, and allogeneic stem cell transplant. We are looking forward to releasing new data later this year on our UCART22 product candidate manufactured in-house,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis. “In addition, we have made progress with our pipeline in 2023 and continue to focus on our core clinical trials BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123). This quarter, Cellectis presented an encore of the clinical data on the AMELI-01 clinical trial at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting. These preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. Cellectis’ innovation team also presented preclinical data on a gene editing process to develop a bona fide HBB gene correction of sickle cell mutation, and a comprehensive analysis to better design efficient TALE Base Editors (TALE-BE) at the International Society for Cell and Gene Therapy (ISCT) 2023 annual meeting. These achievements showcase once more the power of our gene-editing platform and our TALEN®, the technology of choice for therapeutic gene editing, and that we are continuing to deliver constant breakthrough innovation to treat diseases with unmet medical needs. Despite an unprecedented challenging market environment for cell and gene therapy companies, Cellectis remains focused in its mission to develop innovative cancer therapy product candidates.” Pipeline Highlights UCART Clinical Development Programs BALLI-01 (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and is being evaluated in patients with r/r B-ALL in the BALLI-01 Phase 1/2a clinical study. On June 9, Cellectis presented updated clinical and translational data at the European Hematology Association (EHA). These data support the preliminary safety and efficacy of UCART22 in a heavily pretreated r/r B-ALL population. UCART22 is currently the most advanced allogeneic CAR T-cell product in development for r/r B-ALL. In the poster presented at EHA, Cellectis included data from patients who received UCART22 after fludarabine, cyclophosphamide (FC) and FC with alemtuzumab (FCA) lymphodepletion (LD). Compared to the clinical update on BALLI-01 at ASH 2021, we have included data from six additional patients who received UCART22 at dose level 3 (DL3), as of the December 31, 2022 data cutoff. UCART22 administered after FC or FCA LD regimen was well tolerated. No dose limiting toxicities (DLTs) nor immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. For FCA-dose level 3, 50% of the six patients responded. Host lymphocytes remained suppressed through Day 28 for all patients who received FCA LD. Peak ferritin levels correlated with UCART22 cell expansion and cytokine release syndrome (CRS). UCART22 continues to be well tolerated, with no treatment emergent serious adverse events (TESAEs) or DLTs reported. UCART22 cell expansion was detected in 9 of 13 patients in the FCA LD arm and associated with clinical activity. The BALLI-01 study is currently enrolling patients after FCA LD with Cellectis’ in-house manufactured product. The next data set is expected to be released later this year. NATHALI-01 (evaluating UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) UCART20x22 is Cellectis’ first dual allogeneic CAR T-cell product candidate targeting both CD20 and CD22 and is being evaluated in patients with r/r B-NHL in the NATHALI-01 Phase 1/2a clinical study2. The NATHALI-01 clinical study is ongoing. Cellectis expects to provide first-in-human data later this year.AMELI-01 (evaluating UCART123) in relapsed or refractory acute myeloid leukemia (r/r AML) UCART123 is an allogeneic CAR T-cell product candidate targeting CD123 and is being evaluated in patients with r/r AML in the AMELI-01 Phase 1 dose-escalation clinical study. On May 17, Cellectis presented an encore of the clinical data on the AMELI-01 clinical trial that were unveiled at the ASH 2022 annual meeting, at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting. These preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. The oral presentation reviewed preliminary data from patients who received UCART123 at one of the following dose levels: dose level 1 (DL1) 2.5x105 cells/kg; dose level 2 (DL2) 6.25x105 cells/kg; intermediate dose level 2 (DL2i) 1.5x106 cells/kg; or dose level 3 (DL3) 3.30x106 cells/kg after lymphodepletion with FC ([n=8], DL1 – DL3) or FCA ([n=9], DL2 & DL2i). The data presented showed that adding alemtuzumab to the FC LD regimen was associated with sustained host lymphodepletion and significantly higher UCART123 cell expansion, that correlated with improved anti-tumor activity. 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient who failed five prior lines of therapy including allogeneic stem cell transplant experienced a durable minimal residual disease (MRD)-negative complete response that continued beyond 12 months, as of December 2022. The AMELI-01 study is currently enrolling patients after FCA lymphodepletion in a two-dose regimen arm. Research Data & Preclinical Programs UCART20x22 On June 5, 2023, Cellectis presented preclinical data on its product candidate UCART20x22, at the International Society for Cell & Gene Therapy (ISCT) 2023 annual event. Cellectis provided pre-clinical proof-of-concept data for UCART20x22 to overcome current mechanisms of resistance to CAR T-cell therapies in B-NHL, while providing a potential therapeutic alternative to CD19 targeting and allowing a reduction in the time from treatment decision to infusion. Cellectis demonstrated that UCART20x22 displays robust activity in vitro and in vivo, against targets expressing heterogeneous levels of CD22 and CD20. We have used in vitro cytotoxicity assays against different tumor cell lines, showing strong activity whether these cells express a single antigen (CD20 or CD22) or both antigens simultaneously, as well as IFNg release in response to antigen specific stimulation. Article published in Cancer Immunology Research On May 31, 2023, Cellectis published an article in Cancer Immunology Research demonstrating pre-clinical proof-of-concept data of UCART20x22 product candidate, to overcome current mechanisms of resistance to CAR T-cell therapies in B-NHL. In this study, we demonstrated that allogeneic CD20x22 CAR T-cells exhibit robust, sustained and dose-dependent activity in vitro and in vivo, while efficiently targeting primary Non-Hodgkin Lymphoma samples with heterogeneous levels of CD20 and CD22. HBB gene correction of sickle cell mutation Encouraging preclinical data on gene editing process using Cellectis TALEN® technology to develop highly efficient HBB gene correction of sickle cell mutation, were presented in a poster presentation at the ISCT 2023 annual event. These results showed that non-viral DNA delivery associated with TALEN® gene editing reduces the toxicity usually observed with viral DNA delivery and allows high levels of HBB gene correction in long-term repopulating hematopoietic stem cells. Cellectis leveraged TALEN® technology to develop a gene editing process leading to highly efficient HBB gene correction via homology directed repair, while mitigating potential risks associated to HBB gene knock-out. Furthermore, we compared viral (TALEN-V) and non-viral (TALEN-NV) DNA template delivery strategies in mobilized healthy donor (HD) or non-mobilized homozygous sickle patient (HbSS) hematopoietic stem and progenitor cells (HSPCs). Both strategies led to high and comparable efficiencies of HBB gene correction in vitro in HD and HbSS, without affecting viability, purity or clonogenic potential of corrected HSPCs. The poster presentation highlighted the following data: TALEN®-mediated engineering efficiently corrects the mutated HBB gene in clinically relevant HSPCs and promote phenotype correction in fully mature RBCs. Cellectis optimized TALEN® gene editing process mitigates potential safety challenges by reducing the frequency of HBB gene inactivation (<10% β-thal cells). Non-viral DNA template-mediated HBB repair mitigates p53 DNA damage response activation, preserves edited LT-HSCs fitness and enables their efficient engraftment in vivo using an immunodeficient murine model. TALE Base Editors (TALE-BE) A comprehensive analysis to better design efficient TALE Base Editors (TALE-BE) using Cellectis’ TALEN® technology was presented in a poster at ISCT annual meeting. Cellectis developed a strategy that allowed to comprehensively characterize editing efficiencies in function of the TC position within the TALE-BE editing windows. This method is specifically taking advantage of the highly precise and efficient TALEN® mediated ssODN knock-in in primary T cells, allowing to focus on how target composition and spacer variations can affect TALE-BE activity/efficiency. The poster presentation highlighted the following data: Determined optimal spacer length (13/15 bp) for highly efficient TALE-BE for both C40/C40 and C11/C11 scaffolds. Determined optimal common sequence context for high editing rates. Determined that editing efficiency of the C11/C11 scaffold is highly dependent on Cytosine position requirements, resulting in more stringent activity in a context of 15 bp spacer size and decreasing the effects of bystander editing. We believe that the knowledge obtained will allow to better design efficient TALE-BE while improving the specificity profiles of this innovative editing platform. Novel treatment paradigm for successful CAR T immunotherapy against stroma-rich solid tumors On May 12, 2023, Cellectis published an article in Frontiers Bioengineering demonstrating the efficacy of its TALEN® engineered FAP UCART-cells in cancer-associated fibroblast (CAF) depletion, reduction of desmoplasia and tumor infiltration. Over 90% of epithelial cancers including breast, colorectal, pancreatic and lung adenocarcinomas express the CAF-specific surface marker, fibroblast activation protein α (FAP), which makes it a promising CAR T-cell target. In this study, Cellectis proposed a novel and versatile approach of combination CAR T-cell therapy that can be extended to most stroma-rich cold tumors with relevant tumor-antigen targeting CAR T-cells which otherwise are recalcitrant to cell therapy. Preclinical data showed that: In a mouse xenograft model, successful implantation of injected CAFs in the tumors was confirmed by positive staining of spindle-like cells with human-specific FAP antibody, recapitulating a physiologically relevant TNBC tumor with tumor and stromal compartments. FAP UCART-cells alone significantly reduced tumor growth. In vitro and in vivo results show that FAP UCART-cells enable the reprogramming of the cold, stroma-rich triple negative breast cancer (TNBC) TME, making the tumor susceptible to subsequent Meso UCART infiltration and cytotoxicity and improving the overall antitumor activity of the treatment. In the context of combination therapy with anti-PD1 checkpoint inhibitor, maximal anti-tumor activity and survival benefits were observed upon FAP UCART-cell treatment followed by Meso UCART-cell treatment. Licensed Allogeneic CAR T-cell Development Programs Servier and Allogene: anti-CD19 programs Allogene announced that it is enrolling patients “in the industry’s first potentially pivotal Phase 2 allogeneic CAR T clinical trial with ALLO-501A across sites in the United States and Canada”. The European Medicines Agency (EMA) recently approved the ALPHA2 Clinical Trial Application (CTA). Allogene’s single-arm ALPHA2 trial in relapsed/refractory (R/R) large B cell lymphoma (LBCL) will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy. Allogene has announced that it expects to complete enrollment in 1H 2024 with the first data readout by the end of 2024. Long-term follow up data from the Phase 1 of Allogene’s ALPHA/ALPHA2 trials in LBCL was presented at both the American Society of Clinical Oncology (ASCO) Annual Meeting with an encore presentation at the European Hematology Association Congress and International Conference on Malignant Lymphoma (ICML) Lugano in June 2023. The Phase 1 trials enrolled heavily pre-treated patients with a median of three prior lines of therapy. Data from 33 CAR T-naïve LBCL patients receiving Alloy™ cell product including 12 patients treated with the Phase 2 regimen, are the first to demonstrate the potential for an allogeneic CAR T product to induce complete responses at rates and durability similar to approved autologous therapies. Allogene: anti-BCMA and anti-CD70 program The ongoing Phase 1 dose escalation of Allogene’s TRAVERSE study is enrolling patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed on standard therapies including an immune checkpoint inhibitor and a VEGF-targeting therapy. Allogene’s TRAVERSE trial is now deploying an investigational in vitro companion diagnostic (IVD) assay designed to prospectively assess CD70 expression levels in patients. Allogene has announced that dose escalation in the TRAVERSE trial is expected to be completed in 2023. Corporate Updates On June 28, 2023, Cellectis reported results from the annual shareholders’ general meeting held on June 27, 2023, at the Company’s Paris headquarters. At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations. The detailed results of the vote and the resolutions are available on the company’s website: At the end of the meeting, the terms of office of Ms. Annick Schwebig and Mr. Hervé Hoppenot ended and Ms. Annick Schwebig and Mr. Hervé Hoppenot departed the board of directors as of such date. During the annual shareholders meeting, Cécile Chartier, Ph.D., was appointed as a director of the Cellectis’ Board of Directors, with immediate effect. Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc. Prior to her tenure at NextVivo, Dr. Chartier was Vice President of Research at Iovance Biotherapeutics, Inc. where she led the development of next generation tumor-infiltrating lymphocytes (TIL) therapies through research to early-stage clinical trials. Cécile’s extensive experience in the development of next generation cell and gene therapies coupled with her deep knowledge of the U.S. biotechnology industry will be a huge asset to Cellectis. Financial Results The interim condensed consolidated financial statements of Cellectis, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”). We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q2 2023 financial results press release. On January 13, 2023, Calyxt, Cibus Global LLC (Cibus) and certain other parties named therein, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction (the “Calyxt Merger”). As a consequence of the foregoing, Calyxt met the “held-for-sale” criteria specified in IFRS 5 and was classified as a discontinued operation until May 31, 2023. On June 1, 2023, Calyxt and Cibus closed the merger transaction and now operate under the name Cibus, Inc. Consequently, Calyxt was deconsolidated and Calyxt’s cash, cash equivalent and restricted cash are no longer included in the Group’s cash, cash equivalent and restricted cash since June 1, 2023. Cash: As of June 30, 2023, Cellectis, had $89 million in consolidated cash, cash equivalents, and restricted cash. This compares to $95 million in consolidated cash, cash equivalents and restricted cash as of December 31, 2022. This $6 million difference mainly reflects $55 million of cash out, which include $15 million for R&D suppliers, $7 million for SG&A suppliers, $23 million for staff costs, $7 million for rents and taxes, $3 millions of reimbursement of the “PGE” loan, and a $1 million unfavorable impact on Forex partially offset by a $23 million net cash inflow from the capital raise closed in February, a $21 million net cash inflow from EIB loan, a $1 million cash inflow related to the grant and refundable advance from BPI, $2 millions of financial investments’ capital gain and interests, a $1 million reimbursement of social charges paid on stock options, and a $2 million net cash inflow from licenses and other cash receipts. Based on the current operating plan, Cellectis anticipates that the cash, cash equivalents, and restricted cash as of June 30, 2023 will fund Cellectis’ operations into the third quarter of 2024. Revenues and Other Income: Consolidated revenues and other income were $5.6 million for the six months ended June 30, 2023 compared to $6.5 million for the six months ended June 30, 2022. The decrease of $1.0 million reflects the recognition of two milestones related to Cellectis’ agreement with Cytovia for $1.5 million in 2022 and a milestone of $1.0 million with another partner while recognition of revenues in 2023 is not material, and partially offset by the increase of the research tax credit for $0.8 million and the partial recognition of a grant signed with “BPI” of $0.8 million. R&D Expenses: Consolidated R&D expenses were $43.2 million for the six months ended June 30, 2023, compared to $52.2 million for the six months ended June 30, 2022. The $9.0 million decrease was primarily attributable to (i) a $3.4 million decrease in personal expenses due to departures not replaced (ii) a $4.7 million decrease in purchases, external expenses and other (from $28.0 million in 2022 to $23.2 million in 2023) mainly explained by internalization of our manufacturing and quality activities to support our R&D pipeline and (iii) a $0.8 million decrease of non-cash stock-based compensation expenses (from $3.1 million to $2.3 million). SG&A Expenses: Consolidated SG&A expenses were $8.9 million for the six months ended June 30, 2023, compared to $10.9 million for the six months ended June 30, 2022. The $2.0 million decrease primarily reflects (i) a $1.6 million decrease in purchases, external expenses and other (from $6.4 million in 2022 to $4.9 million in 2023) mainly explained by the implementation of our ERP in 2022 (ii) a $0.2 million decrease in personal expenses and non-cash stock-based compensation expenses. Net financial gain (loss): Consolidated net financial gain was $11.6 million for the six months ended June 30, 2023, compared to $9.2 million for the six months ended June 30, 2022. The $2.4 million increase primarily reflects (i) a $20.8 million increase of financial income, mainly attributable to the profit from Calyxt’s deconsolidation, partially offset by (ii) the loss in fair value on our retained investment in Calyxt since deconsolidation for $10.2 million, (iii) a $6.8 million decrease in the fair value of Cytovia’s note receivable. Net income (loss) from discontinued operations: Pursuant to Calyxt deconsolidation income from discontinued operation for the six-month period ended June 30, 2023, 2023 only include five months of activity. The $3.5 million increase of net loss from discontinued operations between the six-month period ended June 30, 2022 and 2023 is primarily driven by (i) the increase of $9.2 million of net financial loss and (ii) the increase of $1.5 million of other operating expenses partially offset by (i) the decrease of $2.8 million of R&D expenses (from $6.3 million in 2022 to $3.5 in 2023) and (ii) the decrease of $4.5 million of SG&A expenses (from $6.8 million in 2022 to $2.3 million in 2023). Net Income (loss) Attributable to Shareholders of Cellectis: The consolidated net loss attributable to shareholders of Cellectis was $40.7 million (or $0.76 per share) for the six months ended June 30, 2023, of which $35.7 million was attributed to Cellectis continuing operations, compared to $50.9 million (or $1.12 per share) for the six months ended June 30, 2022, of which $47.3 million was attributed to Cellectis continuing operations. This $10.1 million decrease in net loss between the first six months of 2023 and 2022 was primarily driven by (i) a $9.0 million decrease of R&D expenses, (ii) a $2.0 million decrease of SG&A expenses and (iii) an increase of $2.4 million of the financial gain due to the deconsolidation of Calyxt compensated in part by the decrease of fair value of Cytovia’s note receivable. These downward impacts on the net loss were partially offset by (i) a decrease of $1.0 million of revenues and other income, (ii) an increase of $1.5 million of loss from discontinued operations attributable to Shareholders of Cellectis. Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: The consolidated adjusted net loss attributable to shareholders of Cellectis was $36.7 million (or $0.68 per share) for the six months ended June 30, 2023, compared to a net loss of $45.5 million (or $1.00 per share) for the six months ended June 30, 2022. Please see “Note Regarding Use of Non-IFRS Financial Measures” for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis. We currently foresee focusing our cash spending at Cellectis for 2023 in the following areas: Supporting the development of our pipeline of product candidates, including the manufacturing and clinical trial expenses of UCART123, UCART22, UCART 20x22 and potential new product candidates; Operating our state-of-the-art manufacturing capabilities in Paris (France), and Raleigh (North Carolina, USA); and Continuing to strengthen our manufacturing and clinical departments. The selected, preliminary financial information set forth above are unaudited and should be considered preliminary and subject to change. We have provided such selected, preliminary results above as our final results remain subject to the completion of our normal closing procedures, final adjustments, developments that may arise between now and the time the financial results are finalized, and management’s and the audit and finances committee’s final reviews. Accordingly, you should not place undue reliance on this preliminary information, which may differ materially from our actual final results. These preliminary results should not be viewed as a substitute for our full quarterly financial statements prepared in accordance with IFRS. In addition, they are not necessarily indicative of the results to be achieved in any future period. These preliminary results have been prepared by and are the responsibility of management. Our independent registered public accounting firm has not audited, compiled, performed any procedures on or revised the preliminary financial information, and accordingly does not express an opinion or any other form of assurance with respect of the preliminary information. We plan to report our full results for the second quarter in the coming days. CELLECTIS S.A. STATEMENT OF CONSOLIDATED FINANCIAL POSITION(unaudited) ($ in thousands) As of December 31, 2022 June 30, 2023 ASSETS Non-current assets Intangible assets 718 695 Property, plant, and equipment 63,621 59,231 Right-of-use assets 44,275 41,457 Non-current financial assets 8,791 13,006 Total non-current assets 117,406 114,389 Current assets Trade receivables 772 422 Subsidies receivables 14,496 19,488 Other current assets 9,078 7,869 Cash and cash equivalent and Current financial assets 97,697 85,505 Total current assets 122,043 113,285 Total assets held for sale 21,768 0 TOTAL ASSETS 261,216 227,674 LIABILITIES Shareholders’ equity Share capital 2,955 3,491 Premiums related to the share capital 583,122 476,224 Currency translation adjustment (28,605 ) (37,050 ) Retained earnings (333,365 ) (305,392 ) Net income (loss) (106,139 ) (40,715 ) Total shareholders’ equity - Group Share 117,968 96,558 Non-controlling interests 7,973 0 Total shareholders’ equity 125,941 96,558 Non-current liabilities Non-current financial liabilities 20,531 40,270 Non-current lease debts 49,358 46,157 Non-current provisions 2,390 2,641 Total non-current liabilities 72,279 89,068 Current liabilities Current financial liabilities 5,088 5,185 Current lease debts 7,872 8,270 Trade payables 21,456 19,229 Deferred revenues and deferred income 59 241 Current provisions 477 1,029 Other current liabilities 13,179 8,093 Total current liabilities 48,131 42,047 Total liabilities related to asset held for sale 14,864 0 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 261,216 227,674 Cellectis S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the three-month period ended June 30, 2023 $ in thousands, except per share amounts For the three-month period ended June 30, 2022 * 2023 Revenues and other income Revenues 1,307 178 Other income 1,416 1,823 Total revenues and other income 2,723 2,001 Operating expenses Cost of revenue (329 ) (55 ) Research and development expenses (25,630 ) (22,144 ) Selling, general and administrative expenses (4,830 ) (3,950 ) Other operating income (expenses) 753 490 Total operating expenses (30,036 ) (25,660 ) Operating income (loss) (27,313 ) (23,659 ) Financial gain (loss) 8,301 15,982 Income tax 0 (258 ) Income (loss) from continuing operations (19,012 ) (7,935 ) Income (loss) from discontinued operations (442 ) (5,647 ) Net income (loss) (19,454 ) (13,583 ) Attributable to shareholders of Cellectis (18,946 ) (10,648 ) Attributable to non-controlling interests (506 ) (2,935 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.42 ) (0.19 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.42 ) (0.19 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations 0.00 (0.05 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations 0.00 (0.05 ) * These amounts reflect adjustments made in connection with the presentation of the discontinued operation CELLECTIS S.A. UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS For the six-month period ended June 30, 2023 $ in thousands, except per share amounts For the six-month period ended June 30, 2022 * 2023 Revenues and other income Revenues 2,972 317 Other income 3,551 5,242 Total revenues and other income 6,523 5,560 Operating expenses Cost of revenue (714 ) (389 ) Research and development expenses (52,231 ) (43,225 ) Selling, general and administrative expenses (10,893 ) (8,914 ) Other operating income (expenses) 774 (83 ) Total operating expenses (63,064 ) (52,612 ) Operating income (loss) (56,541 ) (47,053 ) Financial gain (loss) 9,213 11,580 Income tax 0 (258 ) Income (loss) from continuing operations (47,328 ) (35,731 ) Income (loss) from discontinued operations (6,883 ) (10,377 ) Net income (loss) (54,211 ) (46.108 ) Attributable to shareholders of Cellectis (50,858 ) (40,715 ) Attributable to non-controlling interests (3,352 ) (5,393 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.12 ) (0.76 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.12 ) (0.76 ) Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations (0.08 ) (0.09 ) Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) from discontinued operations (0.08 ) (0.09 ) * These amounts reflect adjustments made in connection with the presentation of the discontinued operation CELLECTIS S.A. DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands) For the three-month period ended June 30, 2022 For the three-month period ended June 30, 2023 $ in thousands Plants (discontinued operations) Therapeutics Total reportable segments Plants (discontinued operations) Therapeutics Total reportable segments External revenues 42 1,307 1,348 1 178 179 External other income - 1,416 1,416 - 1,823 1,823 External revenues and other income 42 2,723 2,765 1 2,001 2,002 Cost of revenue 0 (329 ) (329 ) (63 ) (55 ) (118 ) Research and development expenses (3,419 ) (25,630 ) (29,048 ) (1,322 ) (22,144 ) (23,467 ) Selling, general and administrative expenses (3,585 ) (4,830 ) (8,415 ) (976 ) (3,950 ) (4,927 ) Other operating income and expenses 198 753 951 (1,074 ) 490 (584 ) Total operating expenses (6,806 ) (30,036 ) (36,842 ) (3,435 ) (25,660 ) (29,095 ) Operating income (loss) before tax (6,764 ) (27,313 ) (34,077 ) (3,434 ) (23,659 ) (27,093 ) Financial gain (loss) 6,322 8,301 14,623 (2,213 ) 15,982 13,769 Income tax - - - - (258 ) (258 ) Net income (loss) from discontinued operations (442 ) (442 ) (5,647 ) (5,647 ) Net income (loss) (442 ) (19,012 ) (19,454 ) (5,647 ) (7,935 ) (13,583 ) Non controlling interests 506 - 506 (2,935 ) - (2,935 ) Net income (loss) attributable to shareholders of Cellectis 64 (19,012 ) (18,946 ) (2,712 ) (7,935 ) (10,648 ) R&D non-cash stock-based expense attributable to shareholder of Cellectis 226 1,454 1,681 103 797 900 SG&A non-cash stock-based expense attributable to shareholder of Cellectis 447 557 1,003 326 849 1,174 Adjustment of share-based compensation attributable to shareholders of Cellectis 673 2,011 2,684 428 1,646 2,074 Adjusted net income (loss) attributable to shareholders of Cellectis 737 (17,001 ) (16,264 ) (2,284 ) (6,289 ) (8,573 ) Depreciation and amortization (608 ) (4,500 ) (5,108 ) (12 ) (4,419 ) (4,431 ) Additions to tangible and intangible assets 308 870 1,178 21 311 332 CELLECTIS S.A. DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS – For the six-month period ended June 30, 2023 (unaudited) - ($ in thousands) For the six-month period ended June 30, 2022 For the six-month period ended June 30, 2023 $ in thousands Plants (discontinued operations) Therapeutics Total reportable segments Plants (discontinued operations) Therapeutics Total reportable segments External revenues 73 2,972 3,045 43 317 360 External other income - 3,551 3,551 - 5,242 5,242 External revenues and other income 73 6,523 6,596 43 5,560 5,602 Cost of revenue (0 ) (714 ) (714 ) (63 ) (389 ) (451 ) Research and development expenses (6,297 ) (52,231 ) (58,527 ) (3,487 ) (43,225 ) (46,712 ) Selling, general and administrative expenses (6,801 ) (10,893 ) (17,695 ) (2,313 ) (8,914 ) (11,227 ) Other operating income and expenses 242 774 1,016 (1,251 ) (83 ) (1,334 ) Total operating expenses (12,856 ) (63,064 ) (75,920 ) (7,113 ) (52,612 ) (59,725 ) Operating income (loss) before tax (12,783 ) (56,541 ) (69,324 ) (7,070 ) (47,053 ) (54,123 ) Net financial gain (loss) 5,900 9,213 15,113 (3,307 ) 11,580 8,273 Income tax - - - - (258 ) (258 ) Net income (loss) from discontinued operations (6,883 ) (6,883 ) (10,377 ) (10,377 ) Net income (loss) (6,883 ) (47,328 ) (54,211 ) (10,377 ) (35,731 ) (46,108 ) Non-controlling interests 3,352 - 3,352 5,393 - 5,393 Net income (loss) attributable to shareholders of Cellectis (3,531 ) (47,328 ) (50,858 ) (4,984 ) (35,731 ) (40,715 ) R&D non-cash stock-based expense attributable to shareholder of Cellectis 216 3,134 3,349 188 1,900 2,088 SG&A non-cash stock-based expense attributable to shareholder of Cellectis 789 1,193 1,982 599 1,366 1,965 Adjustment of share-based compensation attributable to shareholders of Cellectis 1,005 4,327 5,331 788 3,265 4,053 Adjusted net income (loss) attributable to shareholders of Cellectis (2,526 ) (43,001 ) (45,527 ) (4,196 ) (32,465 ) (36,663 ) Depreciation and amortization (1,316 ) (9,434 ) (10,749 ) (7 ) (8,875 ) (8,882 ) Additions to tangible and intangible assets 671 1,452 2,123 21 536 556 Note Regarding Use of Non-IFRS Financial Measures Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis. RECONCILIATION OF IFRS TO NON-IFRS NET INCOME For the three-month period ended June 30, 2023 (unaudited) - ($ in thousands except per share data) For the three-month period ended June 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (18,946 ) (10,648 ) Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 2,684 2,074 Adjusted net income (loss) attributable to shareholders of Cellectis (16,263 ) (8,574 ) Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.36 ) (0.15 ) Basic adjusted earnings from discontinued operations attributable to shareholders of Cellectis ($ /share) 0.00 (0.05 ) Weighted average number of outstanding shares, basic (units) 45,497,127 55,583,768 Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (0.36 ) (0.15 ) Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) from discontinued operations 0.02 (0.04 ) Weighted average number of outstanding shares, diluted (units) 45,497,127 55,583,768 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited) First six months ($ in thousands, except per share data) For the six-month period ended June 30, 2022 * 2023 Net income (loss) attributable to shareholders of Cellectis (50,858 ) (40,715 ) Adjustment: Non-cash stock-based compensation expense attributable to shareholders of Cellectis 5,331 4,053 Adjusted net income (loss) attributable to shareholders of Cellectis (45,527 ) (36,662 ) Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.00 ) (0.68 ) Basic adjusted earnings from discontinued operations attributable to shareholders of Cellectis ($ /share) (0.95 ) (0.71 ) Weighted average number of outstanding shares, basic (units) 45,497,127 53,541,010 Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.00 ) (0.68 ) Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) from discontinued operations (0.95 ) (0.71 ) Weighted average number of outstanding shares, diluted (units) 45,497,127 53,541,010 *These amounts reflect adjustments made in connection with the presentation of the discontinued operation About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 23 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). Forward-looking Statements This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate”, “expect”, “plan”, “could” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners. Forward-looking statements include statements about advancement, timing and progress of clinical trials and preclinical studies, the timing of our presentation of data, and the sufficiency of cash to fund operation. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2022 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Investor Relations contacts: Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577 1 Cash position includes cash, cash equivalents and restricted cash. Restricted cash was $5 million as of June 30, 2023. 2 This project is partially funded by the French government, as part of Plan France 2030. On March 8, 2023, BPIfrance and Cellectis entered into a grant and refundable advance agreement to partially support research and development program related to UCART20x22. Attachment Press release earnings Q22023